1. Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial J Am Coll Cardiol. 2016;67(24):2846-2854. doi:10.1016/j.jacc.2016.03.528 Study Flow A total of 723 patients were randomized to intervention (n = 370) or usual care (n = 353); 5.1% and 2.8%, respectively, were lost to follow-up. Figure Legend:

2. Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial J Am Coll Cardiol. 2016;67(24):2846-2854. doi:10.1016/j.jacc.2016.03.528 Primary Outcome The primary outcome, effect of pharmacist care intervention on reduction in estimated risk for cardiovascular (CV) events from baseline to 3 months, found a relative risk reduction between usual care and intervention of 21% (absolute reduction: 5.37%; 95% confidence interval: 4.17 to 6.56; p < 0.001), after adjusting for baseline values and the center effect. Figure Legend:

3. Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial J Am Coll Cardiol. 2016;67(24):2846-2854. doi:10.1016/j.jacc.2016.03.528 3-Month CV Risk Factor Targets At 3 months, pharmacist care (intervention) resulted in significantly more patients reaching the recommended targets for low- density lipoprotein cholesterol (LDL-C) (≤2.0 mmol/l), blood pressure (BP) (<140/90 mm Hg or <130/80 mm Hg if diabetic), glycemic control via glycosylated hemoglobin (HbA1c) (≤7.0%), and current smoking status at the end of follow-up. The absolute differences achieved included: LDL-C, 9.9% (95% confidence interval [CI]: 2.2 to 17.5; p = 0.012); BP, 23.1% (95% CI: 16.0 to 30.1; p < 0.001); HbA1c, 17.6% (95% CI: 9.9 to 25.4; p < 0.001); and smoking, 6.9% (95% CI: 0.6 to 13.2; p = 0.032). CV = cardiovascular. Figure Legend:

4. Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial J Am Coll Cardiol. 2016;67(24):2846-2854. doi:10.1016/j.jacc.2016.03.528 Community Pharmacist Prescribing and Care: Effectiveness in Cardiovascular Risk Reduction To determine whether community pharmacists could improve cardiovascular disease (CVD) risk factor identification and control, patients at high risk for CVD were randomized to usual care or interventions by the pharmacists, with the latter including medication reviews, CVD risk assessment, laboratory tests, medication prescription, and patient education. After 3 months, patients in the intervention group experienced significant decreases in risk for cardiovascular events, as well as blood pressure, cholesterol, glycosylated hemoglobin (HbA1c), and smoking. Figure Legend: